Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999–2003)

Isolates of Streptococcus pneumoniae collected over the first 4 years of the PROTEKT study were tested for susceptibility to penicillin, azithromycin and telithromycin. A total of 20 750 isolates were collected from 39 countries. Penicillin non-susceptibility rates were stable over the study period;...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2005-12, Vol.26 (6), p.479-485
Main Authors: Schito, G.C., Felmingham, D.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Antibacterial resistance
Antibiotics. Antiinfectious agents. Antiparasitic agents
Azithromycin - pharmacology
Biological and medical sciences
Drug Resistance, Multiple, Bacterial
Global Health
Humans
Ketolides - pharmacology
Macrolides
Medical sciences
Microbial Sensitivity Tests
Penicillin
Penicillins - pharmacology
Pharmacology. Drug treatments
Pneumococcal Infections - microbiology
Streptococcus pneumoniae
Streptococcus pneumoniae - drug effects
Telithromycin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Isolates of Streptococcus pneumoniae collected over the first 4 years of the PROTEKT study were tested for susceptibility to penicillin, azithromycin and telithromycin. A total of 20 750 isolates were collected from 39 countries. Penicillin non-susceptibility rates were stable over the study period; overall, 21.8% of isolates were resistant. Azithromycin resistance increased from 31.0% in Year 1 to 36.3% in Year 4. Resistance rates for penicillin and azithromycin varied between countries and were highest in France, Spain, South Africa, USA and the Far East. Multidrug resistance in S. pneumoniae did not change significantly over the 4 years, with an overall rate of 38.6%. Telithromycin retained good activity against S. pneumoniae (0.1% of isolates resistant), including multidrug-resistant isolates.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2005.04.022